OPEN Research Support
head

Professor
Per Pfeiffer
Deparment of Oncology, Odense University Hospital


Projekt styring
Projekt status    Sampling ongoing
 
Data indsamlingsdatoer
Start 01.01.2018  
Slut 31.12.2027  
 



LAPC-03

Short summary

Chemotherapy (FOLFIRINOX) followed by local therapy

(Resection, radiotherapy and/or IRE- irreversibel electo-poration) in patients with locally advanced pancreatic cancer (LAPC)



Rationale



Description of the cohort

Patients with locally advanced pancreatic cancer (LAPC). Patients are not primary resectable.


Data and biological material

Blood for tumormarkers every 8.th week

Questionaires (EORTC QLQ-PAN26)


Primary endpoint :

2 year survival for all patients starting chemotherapy 
Secondary endpoints:Quality of Life (EORTC QLQ-PAN26)PFSOSResponse rate (RECIST v1.1)Histological tumor regression (TRG)Adverse events grade 2-5 (NCI-CTCAE 4.0)Surgical complications, including IRE (Clavien)Number of patients with progression during chemotherapyNumber of patients with R0 resectionEvaluation of biomarkers 


Collaborating researchers and departments

Department of Oncology, Odense University Hospital

  • Per Pfeiffer

Herlev

  • Benny Vittrup Jensen

Aalborg

  • Mette Yilmaz

Aarhus

  • Morten Ladekarl

Stockholm

  • Lars Lundell